biostudies-literatureUnknown29(10)Westin JR<h4>Purpose</h4>Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.<h4>Patients and methods</h4>Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).<h4>Results</h4>FiftClinical cancer research : an official journal of the American Association for Cancer Research1894-1905https://www.ebi.ac.uk/biostudies/studies/S-EPMC10183830biostudies-literatureSafety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.PMC10183830Snider JTLocke FLWestin JRWulf GFarooq Uvan Meerten TShah JKersten MJDickinson MSureda ACheng PTo CUlrickson MLPerales MAJacobson CAFilosto SRapoport APLeslie LOluwole OOWannesson LPagel JMJohnston PGhobadi AElsawy MMiklos DBVardhanabhuti SDu LfalseSafety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.<h4>Purpose</h4>Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.<h4>Patients and methods</h4>Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).<h4>Results</h4>Fift2023-01-01T00:00:00Z2023 May2025-04-05T10:55:24.059Z2025-04-05T10:55:24.059ZS-EPMC101838303699999310.1158/1078-0432.CCR-22-3136